[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intravenous-access\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intravenous-access":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100571975","safe-infusion-study-100571975",false,"NCT06727240","Safe-Infusion Study","A Non-Inferiority Randomized Clinical Trial Investigating Efficacy and Safety of an Innovative Medical Device in the Reduction of Mechanical Complications of Peripheral Intravenous Catheters","Inclusion Criteria:\n\n* The patient has or will get a vascular access device (VAD) expected to be used for continuous or intermittent IV infusion therapy. Continuous IV infusion is defined as an infusion ≥2h and intermitted as an infusion lasting 15min to \\\u003C2h.\n* ≥18 years of age\n* Speak and understand local language\n* VADs already in place when the patient is admitted to the ward should not present with phlebitis or infiltration or occlusion\n* Participants have signed the informed consent or have a legal authorized representative (LAR) who has provided this consent\n\nExclusion Criteria:\n\n* The VAD is expected to be used for sampling only\n* Pregnancy\n* Unable to obtain informed consent or without an available LAR to provide surrogate informed consent\n* Patients under palliative care\n* Bolus IV infusion, defined as an infusion time of \\\u003C15 min","ALL","18 Years",{"count":19,"type":20},548,"ESTIMATED","INTERVENTIONAL",[23],"NA","Around 1.5 billion peripheral intravenous catheters (PIVCs) are sold yearly, with up to 90% of hospitalized patients receiving one, yet failure rates can reach 69%, often due to phlebitis, infiltration, occlusion, or dislodgement. These complications can collectively be named mechanical complications. This study aims to assess a new device's effectiveness in reducing mechanical complications associated with PIVCs through a non-inferiority randomized trial at two sites. A total of 548 patients will be recruited, with primary outcomes focused on complication rates and secondary outcomes examining adverse events, healthcare feedback, and economic impacts.",[26,27],"Intravenous Access","Medical Device","RECRUITING","2024-12-11",{"date":31,"type":32},"2024-12-16","ACTUAL",{"date":34,"type":32},"2024-03-25",{"date":36,"type":20},"2025-03",{"name":38,"class":39},"Interlinked AB","INDUSTRY",2]